---
title: "Jinhe Biotechnology Co., Ltd. (002688.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002688.SZ.md"
symbol: "002688.SZ"
name: "Jinhe Biotechnology Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T12:57:55.677Z"
locales:
  - [en](https://longbridge.com/en/quote/002688.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002688.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002688.SZ.md)
---

# Jinhe Biotechnology Co., Ltd. (002688.SZ)

## Company Overview

Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China and internationally. It offers chlortetracycline premixes; veterinary drug and powder series; disinfectants; and sprinklers. It also engages in the production and sales of feed and raw materials.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.jinhe.com.cn](https://www.jinhe.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.43)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 139 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 20.94% |  |
| Net Profit YoY | -63.52% |  |
| P/B Ratio | 2.00 |  |
| Dividend Ratio | 1.65% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4571277599.91 |  |
| Revenue | 3000156850.51 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 1.69% | C |
| Profit Margin | 1.29% | C |
| Gross Margin | 35.63% | C |
| Revenue YoY | 20.94% | B |
| Net Profit YoY | -63.52% | D |
| Total Assets YoY | 2.38% | C |
| Net Assets YoY | -2.29% | D |
| Cash Flow Margin | 1109.36% | A |
| OCF YoY | 20.94% | B |
| Turnover | 0.52 | C |
| Gearing Ratio | 57.03% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jinhe Biotechnology Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "20.94%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-63.52%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.65%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4571277599.91",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3000156850.51",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "1.69%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "1.29%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "35.63%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "20.94%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-63.52%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.38%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-2.29%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "1109.36%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "20.94%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.52",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "57.03%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 115.61 | 147/215 | 46.00 | 38.14 | 36.35 |
| PB | 1.96 | 82/215 | 2.28 | 2.08 | 1.99 |
| PS (TTM) | 1.50 | 22/215 | 2.03 | 1.79 | 1.67 |
| Dividend Yield | 1.68% | 80/215 | 1.62% | 1.55% | 1.43% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-13T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.82 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002688.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002688.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002688.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002688.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**